The United States market has been flat over the last week but is up 22% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context, identifying high growth tech stocks like Pagaya Technologies can be crucial for investors seeking to capitalize on sectors poised for expansion and innovation.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 24.36% | 24.28% | ★★★★★★ |
Ardelyx | 21.09% | 55.29% | ★★★★★★ |
AVITA Medical | 33.20% | 51.87% | ★★★★★★ |
Bitdeer Technologies Group | 51.56% | 122.57% | ★★★★★★ |
TG Therapeutics | 29.48% | 43.58% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
Alnylam Pharmaceuticals | 21.62% | 56.70% | ★★★★★★ |
Travere Therapeutics | 30.52% | 61.89% | ★★★★★★ |
Blueprint Medicines | 23.52% | 55.88% | ★★★★★★ |
Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pagaya Technologies Ltd. is a technology company that utilizes data science and proprietary AI-powered technology to serve financial institutions and investors across the United States, Israel, the Cayman Islands, and internationally, with a market cap of approximately $769.70 million.
Operations: Pagaya Technologies Ltd. generates revenue primarily through its Software & Programming segment, amounting to $970.90 million. The company leverages data science and AI technology to provide solutions for financial institutions and investors globally.
Pagaya Technologies, amid a flurry of strategic board appointments and significant financial transactions, demonstrates a dynamic approach to governance and market engagement. Recently, the company enhanced its board with financial veterans Asheet Mehta and Alison Davis, signaling a robust strategic direction. Additionally, Pagaya closed a $600 million asset-backed securities transaction, underscoring strong market demand for its AI-driven credit solutions. These moves coincide with an expected annual revenue growth of 15.2% and forecasted earnings growth of 115.87%, positioning Pagaya as an emerging force in tech despite current unprofitability and market volatility.
Explore historical data to track Pagaya Technologies' performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alvotech, with a market cap of $3.78 billion, develops and manufactures biosimilar medicines for patients globally through its subsidiaries.
Operations: The company generates revenue primarily from its biotechnology segment, amounting to $393.92 million. The focus on biosimilar medicines positions it within the global pharmaceutical landscape, leveraging its expertise in development and manufacturing through subsidiaries.
Alvotech, amidst a transformative phase, has shown promising advancements in the biotech sector, particularly with its recent FDA filings for biosimilars which could significantly impact treatment options for inflammatory conditions. With an expected annual revenue growth of 35.5% and earnings forecast to surge by 99% per year, the company is on a robust trajectory despite current unprofitability and a short cash runway. These developments are complemented by strategic partnerships and product approvals that enhance its market presence, notably with Teva Pharmaceuticals enhancing its portfolio with FDA-approved biosimilars like SIMLANDI® and SELARSDITM.
Learn about Alvotech's historical performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Endeavor Group Holdings, Inc. is a sports and entertainment company with operations in the United States, the United Kingdom, and internationally, and has a market cap of approximately $14.45 billion.
Operations: Endeavor Group Holdings generates revenue primarily through its Owned Sports Properties, which contribute approximately $2.96 billion, and its Events, Experiences & Rights segment, accounting for around $2.53 billion. The Representation segment adds another significant portion with $1.61 billion in revenue.
Endeavor Group Holdings, despite a challenging year with a net loss widening to $616.53 million from a previous profit, continues to pay dividends, signaling confidence in its financial health. The firm declared a quarterly dividend of $0.06 per share, maintaining shareholder returns amidst adversity. With earnings forecasted to grow by 41.8% annually, the company's resilience is evident as it navigates through fluctuations in the entertainment sector where it reported substantial revenue growth to $5.54 billion over nine months—an increase from $4.02 billion in the same period last year. This performance underscores Endeavor's potential to stabilize and capitalize on market opportunities despite current volatilities.
Review our historical performance report to gain insights into Endeavor Group Holdings''s past performance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:PGY NasdaqGM:ALVO and NYSE:EDR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。